INFLIXIMAB IN ULCERATIVE COLITIS: REVIEW OF STUDIES AND OWN RESULTS


Cite item

Full Text

Abstract

The article is concerned with international experience of use of infliximab (Remicade) in patients with ulcerative colitis (UC), indicating that this drug is effective for achieving clinical response and induction of clinical remission; influximab accelerates the repair of the mucous membrane of the colon and reduces the frequency of emergency colectomy. Authors present the results of own study, which included 37 patients with UC not underwent surgery. All patients have received Remicade according the Additional pharmacological support program (DLO) for Moscow region in a dose of 5 mg/kg of body weight per day as induction course (3 infusions at the initial, 2-nd and 6-th week) and then every 8 weeks. The effectiveness of infliximab induction therapy was high, positive clinical and endoscopic dynamics was observed in more than 90% of patients receiving the drug. In most cases (96.3%), supportive therapy with Remicade has provided clinical and endoscopic remission or significant improvement. Corticosteroids were abolished more than in 80% of patients, which have received more than 3 infusions of infliximab.

References

  1. Travis S, Stange E, Lemann M, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24-62.
  2. Lawson M, Thomas A, Akobeng A. Tumor necrosis factor alfa blocking agents for induction of remission in ulcerative colitis. Cochrane database Syst Rev 2006;3:CD005112.
  3. Wilhelm S, McKenney K, Rivait K, et al. A review of infliximab use in ulcerative colitis. Clin Ther 2008;30:223-30.
  4. Rutgeerts P, Sandborn W, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;233:2462-73.
  5. Sands B, Tremaine W, Sandborn W, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilit study. IBD 2001;7:83-88.
  6. Probert C, Hearing S. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis. A randomised controlled trial. Gut 2003;52:998-1002.
  7. Белоусова Е.А., Моисеев В.С. Инфликсимаб: 10 лет успешного применения при воспалительных заболеваниях кишечника // Клиническая фармакология и терапия. 2010;19(1):50-54.
  8. Janerot G, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised placebo-controlled study. Gastroenterology 2005;128:1805-11.
  9. Barreiro-de Аscota M, Lorenzo A, Mera J, et al. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohn's Colitis 2009;3(4):271-73.
  10. Cohen RD, Yu AP, Wu EQ, Xie J. et al. Systematic review: costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;(7):693-707.
  11. Sandborn W, et al. ACG Annual Meeting 2005. Abstract 847.Schroeder K, Tremaine W, et al. Coated 5-aminosalicilic acid therapy for mildly to moderately active ulcerative colitis . N Engl J Med 1987;317:1625-29.
  12. Truelove S, Witts L. Cortisone in ulcerative colitis Br Med J 1955;2:1041-48.
  13. Белоусова Е.А. Язвенный колит и болезнь Крона. М., 2002. 140 с.
  14. Colombel J-F, et al. Infliximab, azathioprine or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies